Cubist Systematic Strategies LLC Buys Shares of 194,561 Dynavax Technologies Co. (NASDAQ:DVAX)

Cubist Systematic Strategies LLC acquired a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 194,561 shares of the biopharmaceutical company's stock, valued at approximately $2,485,000. Cubist Systematic Strategies LLC owned 0.15% of Dynavax Technologies at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of Dynavax Technologies by 4.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company's stock worth $51,948,000 after buying an additional 171,933 shares during the period. Renaissance Technologies LLC boosted its position in shares of Dynavax Technologies by 1.8% during the fourth quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company's stock worth $30,077,000 after buying an additional 41,000 shares during the period. Northern Trust Corp boosted its position in shares of Dynavax Technologies by 10.3% during the fourth quarter. Northern Trust Corp now owns 1,457,848 shares of the biopharmaceutical company's stock worth $18,617,000 after buying an additional 135,826 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Dynavax Technologies by 2.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company's stock worth $14,750,000 after buying an additional 32,347 shares during the period. Finally, Bank of Montreal Can boosted its position in shares of Dynavax Technologies by 0.5% during the fourth quarter. Bank of Montreal Can now owns 1,082,180 shares of the biopharmaceutical company's stock worth $13,819,000 after buying an additional 5,099 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Stock Performance

Shares of NASDAQ DVAX opened at $9.41 on Monday. The stock has a 50 day moving average price of $12.24 and a 200 day moving average price of $12.58. Dynavax Technologies Co. has a 52 week low of $9.28 and a 52 week high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a market capitalization of $1.13 billion, a PE ratio of 52.28 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DVAX. StockNews.com cut Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. JMP Securities reduced their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group reduced their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Dynavax Technologies currently has a consensus rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.